SEC Form 4/A · accession 0001209191-19-007704
Vaxart, Inc. · VXRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Michael J. Finney
Director
Period of report
Feb 13, 2018
Accepted (ET)
Feb 6, 2019 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000072444
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 13, 2018 | A | 1,818 | — | A | 230,796 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects additional shares not previously included in the reporting person's Form 4, filed with the SEC on February 15, 2018. These shares were also omitted from Form 4 filed by the reporting person with the SEC on June 8, 2018.
- F2Shares of common stock of the corporation then known as Vaxart Biosciences, Inc. ("Old Vaxart") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 27, 2017, by and among the Issuer, Agora Merger Sub, Inc. and Old Vaxart (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into approximately 0.221 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every 11 shares of common stock outstanding.